The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20170976: KKR & Co. L.P.; Pacific Alternative Asset Management Company, LLC
20170979: Harvest Partners VII, L.P.; Audax Private Equity Fund III, L.P.
20170982: Harvest Partners VII, L.P.; Audax Private Equity Fund IV AIV, L.P.
20170917: MacDonald, Dettwiler and Associates Ltd.; DigitalGlobe, Inc.
20170966: CME Group Inc.; London Stock Exchange Group plc
American Guild of Organists; Analysis to Aid Public Comment; Proposed Consent Agreement
20170967: PTC Therapeutics, Inc.; Paragon Pharmaceutical Capital, LLC
20170968: New Mountain Partners IV, L.P.; Trident Capital Fund - VII LP
20170983: Permira VI L.P. 1; Lyophilization Services of New England, Inc.
20170989: Darden Restaurants, Inc.; Oak Investment Partners XI, L.P.
20170711: Partners HealthCare System, Inc.; Foundation of the Massachusetts Eye and Ear Infirmary, Inc.
20170937: Circassia Pharmaceuticals plc; AstraZeneca PLC
20170898: 40 North Latitude Fund LP; GCP Applied Technologies, Inc.
1704001 Informal Interpretation
1704002 Informal Interpretation
DaVita, RV Management and Renal Ventures
DaVita, Inc. agreed to divest its ownership interest in seven dialysis clinics – five in suburban and urban areas of New Jersey and two on the outskirts of Dallas, Texas – to proceed with its $358 million acquisition of competitor Renal Ventures Management, LLC. DaVita is the second-largest provider of outpatient dialysis services in the United States and Renal Ventures is the seventh-largest. DaVita will divest the seven clinics to PDA-GMF Holdco, LLC, a joint venture between Physicians Dialysis and GMF Capital LLC. Physicians Dialysis has been in business since 1990 and currently operates several outpatient dialysis clinics. According to the FTC's complaint, the acquisition would lead to significant anticompetitive effects in the New Jersey markets of Brick, Clifton, Somerville, Succasunna, and Trenton, and in the Dallas-area markets of Denton and Frisco. Currently, DaVita and Renal Ventures clinics compete directly with each other in these markets, and the merger would represent either a merger to monopoly or a reduction of competitors from three to two. Without that competition, the likely result would be reduced quality and higher prices for dialysis patients. Under the terms of the proposed settlement, DaVita, Inc. must obtain agreements from the medical director of each divested clinic to continue providing physician services after it transfers ownership to PDA-GMF Holdco; obtain consent from the relevant landlords to transfer leases for the facilities to the buyer; and provide the buyer an opportunity to interview and hire employees from the divested clinics. Also under the proposed settlement, DaVita is barred from contracting with the medical directors of the seven clinics for three years, and it must provide transition services for up to 24 months.